Research
Hormonal
GLP-1 receptor agonists impair colonic preparation and delay capsule transit, increasing the likelihood of inadequate bowel cleansing and the need for repeat colonoscopies.
If you take GLP-1s for a colonoscopy, your bowel prep might be less effective than usual. You may need a more intensive prep regimen (like extended clear liquids or additional laxatives) to ensure the doctor can see clearly. This is common and manageable.
GoodSupportsHIGH confidence
GLP-1 RA therapy increases the relative risk of inadequate cleansing by 80%, yielding a number needed to repeat (NNR) of just 14 colonoscopies.
Why this rating
Supported by multiple large observational studies and meta-analyses.
Source
GLP-1 Receptor Agonists and Gastrointestinal Endoscopy: A Narrative Review of Risks, Management Strategies, and the Need for Clinical Consensus
Javier Crespo et al. · Journal of Clinical Medicine · 2025
DOI 10.3390/jcm14155597
narrative_reviewCited 3×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →